Showing 241 - 260 results of 800 for search '"Hepatocellular carcinoma"', query time: 0.08s Refine Results
  1. 241
  2. 242

    Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma by Melchor Alpízar Salazar, Samantha Estefanía Olguín Reyes, Andrea Medina Estévez, Julieta Alejandra Saturno Lobos, Jesús Manuel De Aldecoa Castillo, Juan Carlos Carrera Aguas, Samary Alaniz Monreal, José Antonio Navarro Rodríguez, Dulce María Fernanda Alpízar Sánchez

    Published 2025-01-01
    “…MASLD can progress to Metabolic Dysfunction-Associated Steatohepatitis (MASH), affecting 5.27% globally, leading to severe complications like cirrhosis and hepatocellular carcinoma. <i>Background</i>: Visceral fat distribution varies by gender, impacting MASLD development due to hormonal influences. …”
    Get full text
    Article
  3. 243

    Extrapolating Prognostic Factors of Primary Curative Resection to Postresection Recurrences Hepatocellular Carcinoma Treatable by Radiofrequency Ablation by Hui Ma, Zhongchen Li, Jia Yuan, Lan Zhang, Xiaoying Xie, Xin Yin, Rongxin Chen, Zhenggang Ren

    Published 2021-01-01
    “…Recurrence after curative resection for hepatocellular carcinoma (HCC) is a major cause of death from this disease. …”
    Get full text
    Article
  4. 244
  5. 245

    Hypofractionated Stereotactic Radiotherapy after Transarterial Chemoembolisation Failure in an Unresectable Hepatocellular Carcinoma: A Case Presentation by Francesco Fiorica, Carlo Greco, Sergio Boccia, Sergio Sartori, Antonio Stefanelli, Francesco Cartei, Stefano Ursino

    Published 2013-01-01
    “…Transarterial chemoembolization is the first-line treatment in unresectable hepatocellular carcinoma. There is no standard treatment after transarterial chemoembolization failure. …”
    Get full text
    Article
  6. 246
  7. 247
  8. 248
  9. 249
  10. 250
  11. 251

    Hepatocellular carcinoma risk scores for non-viral liver disease: A systematic review and meta-analysis by Laura Burke, Alexander Hinkson, Vincent Haghnejad, Rebecca Jones, Richard Parker, Ian A. Rowe

    Published 2025-01-01
    “…Background &amp; Aims: Hepatocellular carcinoma (HCC) risk prediction models may provide a more personalised approach to surveillance for HCC among patients with cirrhosis. …”
    Get full text
    Article
  12. 252
  13. 253
  14. 254
  15. 255

    Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment by Lauren Hekman, Eva Napierkowski, Natalie C. Hartman, Jeffrey L. Ellis, Robert H. Wagner, Davide Bova, Maria M. Picken, Robert C. Flanigan

    Published 2023-01-01
    “…Prostate-specific membrane antigen positron emission tomography (PSMA PET) has been approved by the Food and Drug Administration (FDA) to identify prostate cancer in the setting of biochemical recurrence but can also identify other malignancies. 18F-PSMA PET has not been studied as a potential tool for hepatocellular carcinoma (HCC). We describe the case of a 76-year-old male with a rising prostate-specific antigen (PSA) after definitive prostate cancer treatment and no prior liver pathology who was incidentally found to have HCC on 18F-PSMA PET.…”
    Get full text
    Article
  16. 256

    Comparative Analysis of Immunoactivation by Nanosecond Pulsed Electric Fields and PD-1 Blockade in Murine Hepatocellular Carcinoma by Maiweilidan Yimingjiang, Talaiti Tuergan, Xinhua Chen, Hao Wen, Yingmei Shao, RuiQing Zhang, Kasimu Aihaiti, Jing Xue, Tuerganaili Aji, Wei Zhang

    Published 2020-01-01
    “…Nanosecond pulsed electric field (NsPEF) ablation effectively eliminates early-stage hepatocellular carcinoma (HCC) by local ablation and advanced HCC by inducing a remarkable and sustained host immune response. …”
    Get full text
    Article
  17. 257

    Histone lactylation promotes multidrug resistance in hepatocellular carcinoma by forming a positive feedback loop with PTEN by Yuan Zeng, Haoran Jiang, Zhoufeng Chen, Jun Xu, Xiangting Zhang, Weimin Cai, Xianjie Zeng, Peipei Ma, Rong lin, Huilin Yu, Yuanhang He, Huiya Ying, Ruoru Zhou, Xiao Wu, Fujun Yu

    Published 2025-01-01
    “…Abstract FOLFOX (5-fluorouracil, oxaliplatin, folinic acid) is a standard treatment for hepatocellular carcinoma, but its efficacy is often limited by drug resistance, the underlying mechanisms of which remain unclear. …”
    Get full text
    Article
  18. 258

    miR-559 Inhibits Proliferation, Autophagy, and Angiogenesis of Hepatocellular Carcinoma Cells by Targeting PARD3 by Chunjing Wang, Chengcheng Li, Rui Hao

    Published 2022-01-01
    “…Hepatocellular carcinoma (HCC) is one of the most common cancers in the world and has a high mortality rate. …”
    Get full text
    Article
  19. 259

    Quantification of Pregenomic RNA and Covalently Closed Circular DNA in Hepatitis B Virus-Related Hepatocellular Carcinoma by Fugui Bai, Yoshihiko Yano, Takumi Fukumoto, Atsushi Takebe, Motofumi Tanaka, Kaori Kuramitsu, Nungki Anggorowati, Hanggoro Tri Rinonce, Dewiyani Indah Widasari, Masaya Saito, Hirotaka Hirano, Takanobu Hayakumo, Yasushi Seo, Takeshi Azuma, Yonson Ku, Yoshitake Hayashi

    Published 2013-01-01
    “…Thirty-eight hepatocellular carcinoma (HCC) patients, including 14 positive for hepatitis B surface antigen (HBsAg) and 24 negative for HBsAg but positive for anti-hepatitis B core (anti-HBc) antibody, were enrolled in this study. …”
    Get full text
    Article
  20. 260